These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9757136)

  • 41. Active site binding modes of curcumin in HIV-1 protease and integrase.
    Vajragupta O; Boonchoong P; Morris GM; Olson AJ
    Bioorg Med Chem Lett; 2005 Jul; 15(14):3364-8. PubMed ID: 15950462
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene-containing inhibitor: comparisons with molecular modeling.
    Thanki N; Rao JK; Foundling SI; Howe WJ; Moon JB; Hui JO; Tomasselli AG; Heinrikson RL; Thaisrivongs S; Wlodawer A
    Protein Sci; 1992 Aug; 1(8):1061-72. PubMed ID: 1304383
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Developing HIV-1 Protease Inhibitors through Stereospecific Reactions in Protein Crystals.
    Olajuyigbe FM; Demitri N; De Zorzi R; Geremia S
    Molecules; 2016 Oct; 21(11):. PubMed ID: 27809253
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Computational titration analysis of a multiprotic HIV-1 protease-ligand complex.
    Spyrakis F; Fornabaio M; Cozzini P; Mozzarelli A; Abraham DJ; Kellogg GE
    J Am Chem Soc; 2004 Sep; 126(38):11764-5. PubMed ID: 15382890
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Structural role of the 30's loop in determining the ligand specificity of the human immunodeficiency virus protease.
    Swairjo MA; Towler EM; Debouck C; Abdel-Meguid SS
    Biochemistry; 1998 Aug; 37(31):10928-36. PubMed ID: 9692985
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
    Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
    Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming.
    Gehlhaar DK; Verkhivker GM; Rejto PA; Sherman CJ; Fogel DB; Fogel LJ; Freer ST
    Chem Biol; 1995 May; 2(5):317-24. PubMed ID: 9383433
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy.
    Lindberg J; Pyring D; Löwgren S; Rosenquist A; Zuccarello G; Kvarnström I; Zhang H; Vrang L; Classon B; Hallberg A; Samuelsson B; Unge T
    Eur J Biochem; 2004 Nov; 271(22):4594-602. PubMed ID: 15560801
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
    Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezácová P; Brynda J; Pokorná J; Plesek J; Grüner B; Grantz Sasková K; Václavíková J; Král V; Konvalinka J
    J Med Chem; 2008 Aug; 51(15):4839-43. PubMed ID: 18598016
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
    Ghosh AK; Kincaid JF; Walters DE; Chen Y; Chaudhuri NC; Thompson WJ; Culberson C; Fitzgerald PM; Lee HY; McKee SP; Munson PM; Duong TT; Darke PL; Zugay JA; Schleif WA; Axel MG; Lin J; Huff JR
    J Med Chem; 1996 Aug; 39(17):3278-90. PubMed ID: 8765511
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Calculation of relative differences in the binding free energies of HIV1 protease inhibitors: a thermodynamic cycle perturbation approach.
    Reddy MR; Varney MD; Kalish V; Viswanadhan VN; Appelt K
    J Med Chem; 1994 Apr; 37(8):1145-52. PubMed ID: 8164256
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 1.8A X-ray structure of C95M/C1095F double mutant of tethered HIV-1 protease dimer complexed with acetyl pepstatin.
    Prashar V; Hosur MV
    Biochem Biophys Res Commun; 2004 Oct; 323(4):1229-35. PubMed ID: 15451428
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.
    Smith AB; Cantin LD; Pasternak A; Guise-Zawacki L; Yao W; Charnley AK; Barbosa J; Sprengeler PA; Hirschmann R; Munshi S; Olsen DB; Schleif WA; Kuo LC
    J Med Chem; 2003 May; 46(10):1831-44. PubMed ID: 12723947
    [TBL] [Abstract][Full Text] [Related]  

  • 54. X-ray crystal structures of human immunodeficiency virus type 1 protease mutants complexed with atazanavir.
    Klei HE; Kish K; Lin PF; Guo Q; Friborg J; Rose RE; Zhang Y; Goldfarb V; Langley DR; Wittekind M; Sheriff S
    J Virol; 2007 Sep; 81(17):9525-35. PubMed ID: 17537865
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HIV-1 protease flaps spontaneously close to the correct structure in simulations following manual placement of an inhibitor into the open state.
    Hornak V; Okur A; Rizzo RC; Simmerling C
    J Am Chem Soc; 2006 Mar; 128(9):2812-3. PubMed ID: 16506755
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.
    Ghosh AK; Takayama J; Kassekert LA; Ella-Menye JR; Yashchuk S; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4903-4909. PubMed ID: 26096678
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
    Smith AB; Charnley AK; Harada H; Beiger JJ; Cantin LD; Kenesky CS; Hirschmann R; Munshi S; Olsen DB; Stahlhut MW; Schleif WA; Kuo LC
    Bioorg Med Chem Lett; 2006 Feb; 16(4):859-63. PubMed ID: 16298527
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cyclopropane-derived peptidomimetics. Design, synthesis, evaluation, and structure of novel HIV-1 protease inhibitors.
    Martin SF; Dorsey GO; Gane T; Hillier MC; Kessler H; Baur M; Mathä B; Erickson JW; Bhat TN; Munshi S; Gulnik SV; Topol IA
    J Med Chem; 1998 May; 41(10):1581-97. PubMed ID: 9572884
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir.
    Tie Y; Kovalevsky AY; Boross P; Wang YF; Ghosh AK; Tozser J; Harrison RW; Weber IT
    Proteins; 2007 Apr; 67(1):232-42. PubMed ID: 17243183
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oximinoarylsulfonamides as potent HIV protease inhibitors.
    Yeung CM; Klein LL; Flentge CA; Randolph JT; Zhao C; Sun M; Dekhtyar T; Stoll VS; Kempf DJ
    Bioorg Med Chem Lett; 2005 May; 15(9):2275-8. PubMed ID: 15837308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.